Sign In
Buy FIXX
$0.93
+0 (+0%)
At Close: Jun 24, 2024
Homology Medicines Presents New Data Characterizing AAVHSCs as Potential Gene Therapies for Nervous System Disorders
02:00pm, Thursday, 13'th Feb 2020
Homology Medicines, Inc. (FIXX), a genetic medicines company, announced today presentations demonstrating that its proprietary adeno-associated virus vectors derived from hematopoietic stem cells (AAV
Osage University Partners Promotes Kirsten Leute to Partner
03:14pm, Tuesday, 11'th Feb 2020
Osage University Partners, a Philadelphia-based venture capital firm, today announced the promotion of Kirsten Leute to Partner, University Relations.
Homology Medicines (NASDAQ:FIXX) Upgraded at BidaskClub
11:32am, Tuesday, 11'th Feb 2020
BidaskClub upgraded shares of Homology Medicines (NASDAQ:FIXX) from a sell rating to a hold rating in a research report released on Friday morning, BidAskClub reports. FIXX has been the subject of a n
Starboard Buys a Stake in Green Dot, P2 Boosts Its Cott Holdings, and More 13Ds Activity
12:45am, Saturday, 08'th Feb 2020
Activist filings with the SEC on Bloomin’ Brands and five other companies
H.C. Wainwright Sticks to Its Buy Rating for Homology Medicines (FIXX)
12:16pm, Thursday, 06'th Feb 2020
In a report released today, Debjit Chattopadhyay from H.C. Wainwright reiterated a Buy rating on Homology Medicines (FIXX), with a price target of $36.00.
H.C. Wainwright Sticks to Its Buy Rating for Homology Medicines (FIXX)
12:15pm, Thursday, 06'th Feb 2020
In a report released today, Debjit Chattopadhyay from H.C. Wainwright reiterated a Buy rating on Homology Medicines (FIXX – Research
Homology Medicines Inc (NASDAQ:FIXX) Major Shareholder Sells $136,840.65 in Stock
10:47am, Monday, 03'rd Feb 2020
Homology Medicines Inc (NASDAQ:FIXX) major shareholder James E. Flynn sold 8,857 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an averag
-$0.72 Earnings Per Share Expected for Homology Medicines Inc (NASDAQ:FIXX) This Quarter
08:00am, Saturday, 01'st Feb 2020
Equities analysts expect that Homology Medicines Inc (NASDAQ:FIXX) will announce ($0.72) earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Homology
Insiders Roundup: Texas Instruments, Homolody Medicines
04:52pm, Friday, 31'st Jan 2020
Largest insider trades of the week Continue reading...
James E. Flynn Sells 380,256 Shares of Homology Medicines Inc (NASDAQ:FIXX) Stock
09:18am, Friday, 31'st Jan 2020
Homology Medicines Inc (NASDAQ:FIXX) major shareholder James E. Flynn sold 380,256 shares of the company’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price o
Rubius launches early-stage study of lead drug in PKU
05:30pm, Thursday, 30'th Jan 2020
Dosing is underway in a Phase 1 clinical trial evaluating Rubius Therapeutics' (RUBY -4.5%) lead candidate RTX-134, an allogeneic off-the-shelf cell therapy, for the potential treatment of phenylketon
James E. Flynn Sells 193,359 Shares of Homology Medicines Inc (NASDAQ:FIXX) Stock
10:10am, Thursday, 30'th Jan 2020
Homology Medicines Inc (NASDAQ:FIXX) major shareholder James E. Flynn sold 193,359 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of
Codexis Is Chasing a Blockbuster Opportunity. Can It Compete With Gene Therapies?
03:58pm, Tuesday, 28'th Jan 2020
The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
Alpine Global Management LLC Acquires New Position in Homology Medicines Inc (NASDAQ:FIXX)
10:20am, Sunday, 19'th Jan 2020
Alpine Global Management LLC acquired a new stake in Homology Medicines Inc (NASDAQ:FIXX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The f
BioMarin to Begin Early-Stage Study on Gene Therapy for PKU
01:33pm, Tuesday, 14'th Jan 2020
BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
